Prestige Consumer Healthcare Q2 revenue $283.8M, diluted EPS $1.09; reaffirms FY2025 outlook

Prestige Consumer Healthcare Inc.

2025-Q2 EPS reported $2.06 vs consensus $1.01 ▲ beat (+103.9%)

Revenue $283.8M (-0.9% YoY) slightly ahead of expectations; diluted EPS $1.09 vs $1.07 prior year.
North American OTC down 1.9% to $239.8M; International OTC up 5.0% to $44.0M driven by Hydralyte.
Free cash flow $67.8M in Q2; net cash from operations $69.8M, up 11.7% YoY.
Repurchased ~0.2M shares for $12M in Q2; reduced debt by $75M YTD; leverage ratio 2.7x.
Reaffirmed FY2025 outlook: revenue $1,125-1,140M, adj. diluted EPS $4.40-4.46, free cash flow $240M+.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.